Lv6
2970 积分 2021-04-12 加入
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
24天前
已完结
715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study
25天前
已关闭
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
25天前
已完结
Modified Reduction Surgery for Adenomyosis
1个月前
已完结
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
1个月前
已完结
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
1个月前
已完结
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
1个月前
已完结
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
1个月前
已关闭
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
1个月前
已完结
皖公网安备34019202002308
